SCIENTIFIC ARTICLE

Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta-Analysis of Six Randomized Placebo-Controlled Trials

Zhi-min Ying, M.D, Bin Hu, M.D, Shi-gui Yan, M.D

Department of Orthopaedic Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China

Objective: To assess the effectiveness and safety of oral bisphosphonates in increasing bone mineral density (BMD), reducing fractures, and improving clinical function in patients with osteogenesis imperfecta (OI).

Methods: Studies were eligible for inclusion if they were randomized controlled trials of directly comparing oral bisphosphonate therapy with placebo-group in OI patients. Data synthesis regarding to bone mineral density as measured by dual-energy X-ray absorptiometry (DEXA), decreased fracture incidence, change in biochemical markers of bone and mineral metabolism, bone histology, growth, bone pain, quality of life, and others were assessed, and meta-analysis done when possible.

Results: From 98 potential references and six randomized controlled studies a total of 263 participants receiving oral bisphosphonates and 143 placebo treatments contributed data to meta-analysis. Pooled meta-analysis of three studies suggested that there was significant difference between bisphosphonate treated group and placebo in number of patients with at least one fracture (mean difference 0.53, 95% confidence interval 0.32–0.89, \( P = 0.02 \)). Pooled meta-analysis of two studies suggested that significant difference was noted between bisphosphonate treated group and placebo in mean percentage change in spine BMD (T-score) (mean difference 28.43, 95% confidence interval 7.09-49.77, \( P = 0.009 \)). The similar effect was shown in the term of mean change (Z-score) in spine BMD.

Conclusions: Significant improvement in lumbar areal BMD in patients affected with OI has been shown when treated with oral bisphosphonates, even though only a small population was enrolled. We cannot draw a definite conclusion that the increase in BMD can be translated into fracture reduction and clinical functional improvement. The optimal method, dose, type, initiation, and duration of oral bisphosphonates therapy still remains unclear. Well-designed, adequately-powered, placebo-controlled RCTs investigating the effects of oral bisphosphonates on fractures reduction and improvement in quality of life in both children and adults are studied here.

Key words: Alendronate; Clodronate; Etidronate; Oral bisphosphonates; Esteogenesis imperfecta

Introduction

Osteogenesis imperfecta (OI) is an inherited disorder of connective tissue, caused by mutations in the genes that encode type I collagen\(^1\)–\(^3\). OI is characterized by increased bone fragility of varying severity and low bone mass\(^4\)–\(^5\). It commonly presents with joint hypermobility, blue or grey-blue scleral color, dentinogenesis imperfecta, and premature hearing loss. This genetic rare disease is almost always caused by mutations in one of the two genes encoded with type I \(\alpha\) chains (\(COL1A1\) and \(COL1A2\))\(^6\)–\(^7\). The incidence of osteogenesis imperfecta is estimated to be between one and two per 20000 people\(^8\)–\(^10\). Normal bone matrix is composed of 10% non-collagenous
proteins and 90% type I collagen fibers which provide bone resilience. Individuals with OI have less and/or poorer quality type I collagen than unaffected people, causing their bones to deform and/or fracture. Further refinement of these classifications was made with molecular genetic analyses. Recently, the addition of OI types V, VI and VII have been proposed. It is unclear whether OI types V, VI and VII will be classified with OI in the future as these individuals do not have evidence of type I collagen mutations.

Intravenous and oral bisphosphonates are first-line established therapy for the treatment of most patients with osteoporosis, with proven efficacy to reduce fracture risk at the spine, hip, and other nonvertebral skeletal sites. Bisphosphonates act by inactivating osteoclasts, the cells that break down bone tissue, thereby inhibiting bone resorption. There are two different types of bisphosphonates, nitrogenous and non-nitrogenous. Nitrogenous bisphosphonates including alendronate, eridronate, olpadronate, pamidronate, risedronate and zolendronate disrupt osteoclast formation, survival and cytoskeletal dynamics. Non-nitrogenous bisphosphonates including clodronate and etidronate and tiludronate initiate osteoclast apoptosis. The bisphosphonates vary in their efficacy and absorption when taken orally, making direct comparison challenging. They increase the areal bone mineral density (BMD) and reduce the incidence of osteogenesis imperfecta. Beneficial effects have also been reported in children with osteogenesis imperfecta.

Several important quasi-randomized or randomized controlled trials presented increase of BMD and decrease of reported fracture rates in children or adults with osteogenesis imperfecta by cyclic intravenous neridronate and pamidronate. It is unclear whether OI types V, VI and VII will be classified with OI in the future as these individuals do not have evidence of type I collagen mutations.

Intravenous and oral bisphosphonates are first-line established therapy for the treatment of most patients with osteoporosis, with proven efficacy to reduce fracture risk at the spine, hip, and other nonvertebral skeletal sites. Bisphosphonates act by inactivating osteoclasts, the cells that break down bone tissue, thereby inhibiting bone resorption. There are two different types of bisphosphonates, nitrogenous and non-nitrogenous. Nitrogenous bisphosphonates including alendronate, eridronate, olpadronate, pamidronate, risedronate and zolendronate disrupt osteoclast formation, survival and cytoskeletal dynamics. Non-nitrogenous bisphosphonates including clodronate and etidronate and tiludronate initiate osteoclast apoptosis. The bisphosphonates vary in their efficacy and absorption when taken orally, making direct comparison challenging. They increase the areal bone mineral density (BMD) and reduce the incidence of osteogenesis imperfecta. Beneficial effects have also been reported in children with osteogenesis imperfecta.

Several important quasi-randomized or randomized controlled trials presented increase of BMD and decrease of reported fracture rates in children or adults with osteogenesis imperfecta by cyclic intravenous neridronate and pamidronate. But treatment with intravenous bisphosphonate needs medication at regular intervals at home or during hospital stays. This invasive and inconvenient medication administration unavoidably affects schooling, distracting parents from their work commitments. The intravenous administration is also unfriendly to the patients especially to the children. Oral treatment provides merits in terms of convenience, cost, and reduced individual distress. Therefore, there is still no definite conclusion as to whether oral administration of bisphosphonate can improve quality of life in adults and children with osteogenesis imperfecta, especially regarding the reduced fracture rate.

The purpose of this study was to conduct a systematic review and meta-analysis of recent studies to address if oral bisphosphonate therapy for osteogenesis imperfecta was equivalent to the placebo group regarding bone mineral density as measured by dual-energy X-ray absorptiometry (DEXA), decreased fracture incidence, lessening of deformity, reduced pain, and improved growth and mobility. Our hypothesis was that the oral bisphosphonate therapy would offer the patients with improved quality of life and reduced fracture rate than placebo group.

### Methods

#### Inclusion and Exclusion Criteria

Studies were eligible for inclusion if they were randomized controlled trials that directly compared oral bisphosphonate therapy with placebo-group in OI patients, and measured primary outcomes of bone mineral density as measured by dual-energy X-ray absorptiometry (DEXA), decreased fracture incidence, lessening of deformity, reduced pain, and improved growth and mobility (Table 1). These variables were selected because at least half of the studies included each of these measures. Children (defined as age 0 to 18 years) and adults with OI diagnosed using accepted diagnostic criteria, based on clinical or laboratory findings, or both, were eligible. Individuals affected with all types of OI are included in this review. We excluded randomized controlled trials in which any enrolled patients received the bisphosphonate therapy using IV administration. Although pathology features harvested from the operated site would be the ideal outcome measure, this would require following large number of participants for decades. No such studies have been done, so we used the various Clinical Scores System and radiologic results as surrogate outcomes, as are commonly used in patients. Clinical Scores System and radiologic results have been associated with clinical effects.

#### Searching Strategy and Selection Method

Review protocol described by Spindle et al. and Wright et al. were employed. The electronic literature search was last updated on 28 August 2019. Without language restrictions, we searched the Medline (1966-present), Cochrane Central Register of Controlled Trials, and EMBASE.

#### Table 1: PICOS criteria for inclusion and exclusion of studies

| Parameter | Inclusion criteria | Exclusion criteria |
|-----------|--------------------|--------------------|
| Patients  | Children (defined as age 0 to 18 years) and adults with OI diagnosed using accepted diagnostic criteria, based on clinical or laboratory findings, or both. Individuals affected with all types of OI are included in this review. | Randomized controlled trials in which any enrolled patients who receive the bisphosphonate therapy using IV administration. |
| Intervention | Oral Bisphosphonate | Studies without defined clinical outcomes |
| Comparator | Placebo | - |
| Outcomes | Bone mineral density as measured by dual-energy X-ray absorptiometry (DEXA), decreased fracture incidence, lessening of deformity, reduced pain, and improved growth and mobility. | - |
| Study design | Randomized controlled trials | Non-randomized controlled trials; Retrospective, prospective, or concurrent cohort studies; Cross sectional studies |
(1980-present), CINAHL (1982 to present), AMED (1985 to present), and ISI Web of Science (1945 to present) for the terms "oral bisphosphonate", "alendronate", "clodronate", "etidronate", "ibandronate", "olpadronate", "risendronate", "tiludronate", and "osteogenesis imperfecta". The nine terms were searched individually and were combined with Boolean terms. No exclusions such as publication year or journal name were specified in the search strategy. We manually searched conference abstracts and key journals for 2000–2019: European Journal of Pediatrics, Journal of Pediatric Orthopaedics, The Journal of Bone and Joint Surgery (Am or Br version), The Journal of Clinical Endocrinology and Metabolism, Clinical Orthopaedics and Related Research, and the Journal of Bone and Mineral Research. We examined the reference lists and ISI citations of all included studies. Two reviewers assessed potentially relevant articles against the inclusion criteria. Inclusion criteria included English-language Level I of evidence studies involving directly comparing the effects of oral bisphosphonates in all types of OI. Exclusion criteria included non-randomized controlled studies, intravenous bisphosphonate, and follow-up of the study population less than 70%. PubMed searches from 1966 to 2019 using MESH terms, "osteogenesis imperfecta", “randomized controlled trial”, and "Randomised Controlled Trials," were also carried out by the authors.

Data Collection
Two reviewers (Zhi-min Ying, Bin Hu) independently reviewed each abstract and extracted data. The references for each of these studies also were examined for other relevant studies. If there were any discrepancies, a third individual reviewed the articles. We extracted change between the two different therapies in bone mineral density as measured by dual-energy X-ray absorptiometry (DEXA), decreased fracture incidence, change in biochemical markers of bone and mineral metabolism, bone histology, growth, bone pain, quality of life. Two reviewers independently assessed each trial’s risk of bias, assessing factors such as randomization, allocation concealment, blinding, completeness of outcome assessment, and selective reporting. Where necessary we contacted authors to obtain information on primary outcome factors.

Assessment of Risk of Bias in Included Studies
We assessed the methodological quality of the trials based on the method described by Jüni25. In addition, we described the generation of allocation sequence and concealment of allocation sequence as adequate, inadequate, or unclear. We also evaluated each trial for the degree of blinding and whether an intention-to-treat analysis was undertaken. The methodological quality ratings, and details as to why they assigned these ratings for each criterion was presented (Table 2). The authors have presented methodological quality ratings, and details as to why they assigned these ratings for each criterion. However, studies were not weighted on the basis of their assigned methodologic quality.

Data Analysis
We converted all the different outcomes to standardized mean differences, calculating a standardized mean difference of hanged from base-line in treatment and control groups. Where clinically useful, we estimated a benefit in units of percentage change since baseline from the standardized mean differences by estimating the pooled standard deviation from the means of the standard deviation of the outcomes in double-row and single-row groups for each study, and multiplying the standardized mean differences by this.

We calculated statistical heterogeneity using a $\chi^2$ test on N-1 degrees of freedom, with significance conservatively set at 0.10. We also assessed inconsistency I² using the formula $[(Q-df)/Q] \times 100\%$, where Q is the $\chi^2$ statistic and df is its degrees of freedom, to describe the percentage of the variability in effect estimates due to heterogeneity. We considered a value greater than 50% as denoting substantial heterogeneity. For each study, relative risks (RRs) with 95% confidence intervals (CIs) and standardized or weighted mean differences with 95% CIs were calculated for dichotomous outcomes and continuous outcomes, respectively.

A fixed-effects or random-effects model was applied dependent on the heterogeneity of the studies. Quality appraisal was performed according to the CONSORT 2010 checklist and Cochrane scale was used to assess the risk of bias26. When heterogeneity was considered substantial, we explored its causes by carrying out pre-specified subgroup analyses where data were available; that is, subgroup by sex, tear size, base profiles, compliance, and adequacy of allocation concealment. Where there weren’t clear clinical reasons or study methodology reasons for substantial heterogeneity between studies, we proceeded to meta-analysis using random-effects models. All analyses were carried out in Review Manager 5 (Computer program. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.). When possible we used intention to treat data in analyses, but if these were not available we used, in order of preference, data from available data or per protocol analyses. Assessment of publication bias was by funnel plot.

Results
Description of Studies
Of the 13 studies were identified and reviewed, six randomized placebo-controlled trials met the inclusion criteria and were included in this comparison22,27–31 (see Fig. 1). Of these six randomized controlled studies, a total of 263 participants receiving oral bisphosphonates and 143 placebo treatments contributed data to meta-analysis. Further details of the characteristics of included studies can be obtained in Tables 3 and 4. Trials were excluded if they are not RCTs or they did not evaluate effect of medicine bisphosphonate on OI patients or they did not assess the clinical outcome as in the form of bone density or fracture reduction. Five trials are investigating the effect of oral bisphosphonate clinical results in adults with osteogenesis imperfecta while only one trial...
studied the effect of oral bisphosphonate in children with osteogenesis imperfecta. They all have two studies that evaluated alendronate, risedronate and olpadronate separately.

**Risk of Bias in Included Studies**

Despite differences in methodological quality, the results of each study were considered equally and were not weighted in the analysis. Further details of the methodological quality of the included studies can be found in Table 2.

Sakkers and Chevrel trials\(^27,28\) were described as randomized, by computer-generated random numbers and were deemed adequate. The Chevrel trial was described as double-blinded (study personnel and participants). For all the trials, an intention-to-treat analysis was undertaken. Two participants (one study personnel and participants), using a matched placebo, were accounted for in the final analysis. It was also reported that an intention-to-treat analysis were performed in the Chevrel trial.

**Primary Outcomes**

**Number of Patients with at Least One Fracture**

Each of the five trials reported on this outcome including three studies in children\(^27,30,31\) and one trial in adults\(^28\). The Sakkers trial reported a 31% reduction in relative risk for fracture after treatment with oral olpadronate, and, when analyzed in the review, this produced a hazard ratio of 0.69 (95% CI 0.52 to 0.91) and a significantly decreased fracture number and relative rate (RR) 0.40 (95% CI 0.24 to 0.69)\(^27\). The Chevrel trial showed that the incidence of vertebral and peripheral fractures was not significantly different between the alendronate and placebo groups. Two vertebral and 17 peripheral fractures occurred in 11 patients in the placebo group versus no vertebral and 17 peripheral fractures in 10 patients in the alendronate group\(^28\). Similar results are further confirmed by Ward et al.\(^30\). They reported that 83% of the ALN patients and 92% of placebo patients sustained at least one investigator-reported fracture (\(P = 0.070\)).

Pooled meta-analysis of three studies\(^27,30,31\) suggested that there was significant difference between bisphosphonate treated group and placebo group in number of patients with at least one fracture (mean difference 0.53, 95% confidence interval 0.32–0.89, \(P = 0.02\)) (Fig. 2).

**Change in Bone Mineral Density (BMD) as Assessed by DEXA**

**Mean Percentage Change and Mean Change (Z-score) in Spine BMD**

Each of the five trials reported on this outcome\(^27–31\). Analyses of unadjusted and adjusted for baseline group differences in general characteristics both indicated a greater rise in spinal DXA values with olpadronate than with placebo.
Pooled meta-analysis of two studies suggested that significant difference was noted between bisphosphonate treated group and placebo in mean percentage change in spine BMD (T-score) (mean difference 28.43, 95% confidence interval 7.09–49.77, \( P = 0.009 \)). The similar effect was shown in the term of mean change (Z-score) in spine BMD. Meta-analysis of three studies29–31 showed that the bisphosphonate treated group presented significantly higher Z-score compared with placebo group (mean difference 5.70, 95% confidence interval 1.30–10.11, \( P = 0.01 \)) (Fig. 3).

**Mean Percentage Change in Total Femur BMD**

Only two trials reported on this outcome28,29. Chevrel et al. reported that the mean observed change in total femur BMD in the alendronate treated groups and placebo groups was +0.024 ± 0.004 and −0.002 ± 0.005 \( \text{g/cm}^2 \), respectively. This increase in the alendronate group was significantly greater compared with placebo groups (\( P = 0.001 \)). The increase in the alendronate group was significantly greater than that in the placebo group; total femur BMD, MD 3.00 (95% CI 2.73 to 3.27)28. However, another study conducted by Rauch et al. showed that there was no significant difference between the risedronate treated groups and placebo groups for changes in DXA parameters for hip [Mean (SD), Risedronate: 12.4 (10.8); Placebo: 6.5 (5.9), \( P = 0.11 \)]29. As these two trials involve two different populations (children and adults), the meta-analysis cannot be performed.

**Secondary Outcomes**

**Change in Biochemical Markers of Bone and Mineral Metabolism**

There were five clinical trials that reported on this outcome27–31. There were different markers selected for study in the included trials so direct comparison could not be performed. Sakkers et al. reported no significant change was found in urine or serum markers (serum concentrations of creatinine, \( \gamma \)-glutamyl transpeptidase, aspartate and alanine aminotransferases) between the olpadronate and placebo groups27. A decrease in bone resorption markers (collagen peptides, osteocalcin) was detected by Chevrel et al. in the alendronate-treated groups, while the levels of alkaline phosphatase remained unchanged28. In 2009, Rauch et al. also showed that there were no significant differences between the risedronate-treated and placebo groups in terms of the serum levels of phosphorus, creatinine, 25-hydroxy vitamin D, 1,25-dihydroxy vitamin D, PTH, urinary calcium/creatinine ratio, alanine aminotransferase, aspartate...
aminotransferase, and complete blood count. A significant rise in PTH levels was observed only at month 3 in the ALN treated groups compared with the placebo group ($P = 0.049$). Also statistically significant difference was found in the ALN treated groups in 1, 25-dihydroxy vitamin D at month 24 compared with the placebo group ($P = 0.048$). uNTx levels decreased significantly in the groups treated with ALN than in the placebo groups ($P = 0.001$). However, there was no significant treatment difference between the two groups with regard to changes in serum total alkaline phosphatase activity. Significant mean percentage decreases were both observed in urine NTx/creatinine and serum bone specific alkaline phosphatase concentration at 3 and 6 months in the risedronate group, while significant difference was noted between the risedronate and placebo groups at months 6 and 12 for both markers.

**Bone Histology**

There were two studies that showed histology results. Histomorphometric analysis of these samples by iliac bone biopsies showed that bone formation and resorption parameters, bone size, cortical width, or the amount of trabecular bone were similar between the risedronate and placebo groups. Transiliac histomorphometric safety data showed the ALN group had a significant reduction in osteoid volume per bone volume after treatment. This difference between treatment groups was highly significant in the semiquantitative evaluation of iliac bone samples which were obtained at the end of the treatment period revealing the presence of at least one large osteoclast (>50 mm). However, no significant treatment difference was found between the two groups regarding the presence of calcified cartilage.

| TABLE 3 Demographics of clinical studies included in meta-analysis |
|---------------------------------------------------------------|
| **Study ID** | **Interventions** | **Number of patients** | **Mean age (SD)** | **Women/Male** | **Osteogenesis Imperfecta (OI) Type** | **Duration** |
|----------------|-------------------|------------------------|------------------|---------------|-------------------------------------|-------------|
| Sakkers 200427 | Olpadronate       | 16                     | 10.0 (3.1)       | 7/9           | Type I 4, Type III 4, Type IV 8     | 2 years     |
| Chevrel 200628 | Alendronate       | 31                     | 36 (12)          | 15/33         | Type I 29, Type IV 2                | 3 years     |
| Kok 200722    | Olpadronate       | 16                     | 10.0 (3.1)       | 7/9           | Type I 4, Type III 4, Type IV 8     | 2 years     |
| Chevrel 200628 | Placebo           | 18                     | 10.7 (3.9)       | 11/7          | Type I 9, Type III 5, Type IV 4     |             |
| Kok 200722    | Placebo           | 18                     | 10.7 (3.9)       | 11/7          | Type I 9, Type III 5, Type IV 4     |             |
| Rauch 200929  | Risedronate       | 13                     | 11.7 (3.6)       | 5/8           | Type I 13                           | 2 years     |
| Ward 201130   | Alendronate       | 109                    | 11.0 (3.6)       | 47/62         | Type I 76, Type III 2, Type IV 11,  |
|                |                   |                        |                  |               | Type III 3, Type IV 6, Unknown 5    |             |
| Placebo       | 30                | 11.0 (4.0)             | 14/16            |               | Type I 37, Type III 3, Type IV 6, Unknown 3 |             |
| Bishop 201331 | Risedronate       | 94                     | 8.9 (3.4)        | 49/45         | Type I 60, Type II 16, Type III 2, |
|                |                   |                        |                  |               | Type IV 11, Unknown 5               |             |
| Placebo       | 49                | 8.6 (3.1)             | 22/27            |               | Type I 29, Type II 8, Type III 3, Type IV 6, Unknown 3 | 1 year + another 2 years in open-label |

Type I, Autosomal dominant Fractures with little or no limb deformity, blue sclera, normal stature, hearing loss, dentogenesis imperfecta rare; Type II Autosomal dominant Lethal perinatal type: undermineralized skull, micromelic bones, “beaded” rib on x-ray, bone deformity, platyspondyly; Type III Progressive deforming type: limb deformities, sclera hue varies, very short stature, dentogenesis imperfect common; Type IV Sclerae blue, grey, grey/blue, or white, mild/moderate limb deformity with fracture, variable short stature, dentogenesis imperfect common, some hearing loss.
| Study ID       | Biochemical markers                                      | BMD                  | Fracture incidence                                      | Growth | Bone pain                       | Quality of life               |
|---------------|---------------------------------------------------------|----------------------|----------------------------------------------------------|--------|-------------------------------|------------------------------|
| Sakkers 2004  | No differences was found in the terms of urinary markers of bone resorption as well as serum concentrations of creatinine, γ-glutamyl transpeptidase, and aspartate and alanine aminotransferases between the two groups. | Unadjusted and adjusted analyses both indicated a greater rise in spinal DXA values with olpadronate than with placebo. Increase spine z score 1.67 SD vs no significant change placebo. | Opadronate treatment was associated with a 31% reduction in relative risk of fracture of long bones (hazard ratio 0.69 [95% CI 0.52–0.91], P = 0.041). | No significant change | Not addressed | No significant difference in mobility/ambulation; muscle strength or selfcare |
| 2006 Chevel   | Decrease in bone resorption markers (collagen peptides, osteocalcin). Alkaline phosphatase unchanged. | Increase spine and femur BMD. | No difference was seen in terms of vertebral or peripheral fracture rate between two groups. Not adequately powered. | No difference | No difference in pain during the study except an increase with alendronate at 36 month | Not addressed |
| Kok 2007      | None | None | None | None | None | Health utility index/mark III and self-perception profile for children |
| Rauch 2009    | Treatment with risedronate was significantly more effective than treatment with placebo in decreasing serum NTX. No significant treatment difference was observed with regard to changes in the other markers of bone and mineral metabolism: Serum alkaline phosphatase, serum CICP, TRACP5b, urine Ca/creatinine, NTX/creatinine. | DXA showed that risedronate Treatment was associated with a larger increase in lumbar spine BMC and BMD, whereas Changes in lumbar Spine bone projection Area did not differ between groups. No significant difference between The risedronate and placebo groups. | The Number of fractures per patient ranged from 0 to 2 in the risedronate group and from 0 to 4 in the placebo cohort. None of these outcomes concerning fractures was significantly different between groups. | There were also no detectable treatment differences regarding changes in the shape of lumbar vertebral body and cortical thickness of the second metacarpal bone. Qualitative evaluation of radiographs did not show any signs of sclerosis in the metaphyses of long bones. | The number of patients suffering from bone pain at the end of the study was four in the risedronate group and four in the placebo group. None of these outcomes concerning bone pain was significantly different between groups. | Treatment differences in the changes of grip force were not statistically significant |
| Ward 2011     | No significant differences between the ALN and placebo groups were observed for changes between baseline and month 24 in serum levels of calcium, phosphorus, creatinine, and urinary calcium to creatinine ratio. The difference in 1, ALN increased spine areal BMD by 51% vs a 12% increase with placebo (P = 0.0001); the mean spine areal BMD z-score increased significantly from -4.6 to -3.3 (P < 0.001) with ALN, where as the change in the placebo group (from The relative risk (95% CI) of having at least one new radiographically confirmed long-bone fracture between baseline and month 24 was 1.04 for the ALN group, which was not significantly different from 1.00. 83% of the ALN patients and 92% of placebo patients | The mean midline vertebral height was similar between the two groups | Significantly fewer ALN patients experienced bone pain at month 24 than at baseline. The difference between the two groups in terms of the percentage of patients who suffered bone pain was not statistically significant and no | No statistically significant differences in self-care or mobility; functional skills scaled scores and in grip force was found between the ALN and placebo groups |
Growth

Three trials reported on this outcome. Sakkers et al. reported no difference was shown in seated height or radiographic assessments of lumbar vertebral height between olpadronate treated groups and placebo at final follow-up. Rauch et al. also demonstrated that no detectable treatment differences were observed regarding changes in the shape of lumbar vertebral bodies and cortical thickness of the second
metacarpal bone. The mean midline vertebral height was also similar between the ALN and placebo groups ($P = 0.444$).

### Bone Pain

Three trials reported bone pain change. Chevrel et al. reported that the pain score was similar in the two groups from 0 to 30 months and reported end-of-trial data that showed an increase at final follow-up with alendronate treated groups (mean 1.30, 95% CI 0.14 to 2.46). Also, another study confirmed the results that there was no significant difference between these two groups. However, one trial completed by Ward et al. reported that significantly fewer ALN patients experienced bone pain at month 24 than at baseline ($P = 0.001$). But there was no significant difference between the ALN and placebo groups in the percentage of patients who experienced bone pain ($P = 0.065$). As these two trials involving different populations (children and adults), the meta-analysis cannot be performed.

### Quality of Life

Five included trials evaluated at least one quality of life outcome. Sakkers reported that no changes were found in the changes of grip or hip flexor strength or mobility when comparing olpadronate to placebo, and the difference in changes was found to be similar between the two groups. Hearing was assessed in the study by Chevrel et al., which found no difference between the alendronate-treated group and placebo group (mean: -0.10, 95% CI -2.88 to 2.68). No statistically significant difference was observed by two studies in self-care or mobility functional skills scaled scores and in grip force. We found only slight differences in quality of life, which was measured using self-perception profile for children (SPPC) and health-utility index (HUI) in favor of the bisphosphonate group. A small but not significant decrease in pain was detected in the bisphosphonate group.

### Discussion

Six randomized controlled studies were included in our systematic and meta-analysis. Two studies conducted by Sakkers et al. and Kok et al. reported on the same patient groups with olpadronate but involving different results: the former focuses on skeletal effects and functional outcomes while the latter one focuses on quality of life. Five trials are investigating the effect of oral bisphosphonate clinical results in children with osteogenesis imperfecta while only one trial studies the effect of oral bisphosphonate in adults with osteogenesis imperfecta. Five studies enrolled children and one enrolled adults.

All the included studies investigated changes to varying degrees in BMD, fracture rate, markers of bone turnover, growth, pain, and quality of life with bisphosphonate therapy. For a summary of outcomes reported by different trials, see Table 4. All studies assessing BMD independently reported significant increases after treatment with either oral or IV bisphosphonate and at separate sites (spine, hip, femur). However, it is difficult to compare all these trials directly as different populations were included (adults versus children; for accurate comparisons children cannot be compared to adults due to high bone turnover during childhood and adolescence and open epiphyses). Additionally, different reporting indices were used (Z-score versus total BMD). But...
data from some of these studies can contribute to the analysis when the same population and reporting indices were employed as well as the same locations were measured. Pooled meta-analysis of two studies suggested that significant difference was noted between bisphosphonate treated group and placebo in mean percentage change in spine BMD (mean difference 28.43, 95% confidence interval 7.09–49.77, \( P = 0.009 \)). A similar effect was shown in the term of mean change (Z-score) in spine BMD by three studies. Both randomized and non-randomized studies all reported that oral bisphosphonate therapy has shown increases in BMD. The majority of the patients enrolled by Bishop et al. and Sakkers et al. were children with mild forms of the disease. They concluded that the oral bisphosphonate treatment is not suited to severe types of OI, but is suited to mild types. The effect of oral bisphosphonate in increasing and reducing fracture rates in BMD are consistent with those treated by intravenous bisphosphonate in uncontrolled, observational studies and randomized controlled trial. Each of the four trials reported on this outcome including three studies on children and one trial on adults. As mentioned before, an increase in the growth and BMD in children and adolescents with OI, together with the trend for decreased fractures, makes data comparison from all the trials extremely difficult. The meta-analysis was performed when the same indices were reported among the studies. Pooled meta-analysis of three studies suggested that there was significant difference between bisphosphonate treated group and placebo group in the number of patients with at least one fracture (mean difference 0.53, 95% confidence interval 0.32–0.89, \( P = 0.02 \)).

Improvement in the height of vertebral bodies and cortical width has been shown among the children with OI treated with IV bisphosphonate. Similar increases were observed by DiMeglio et al. in terms of the height of vertebral bodies between high-dose oral bisphosphonate and IV treatment. In contrast, the oral bisphosphonate (alendronate, risedronate and olpadronate) therapy was successful in increasing the lumbar BMD but was not accompanied by improvement in other skeletal parts such as metacarpal and iliac cortical width. One explanation for this phenomenon is that primary and secondary spongiosa are the main component of the vertebral body. More and more primary spongiosa are converted to secondary spongiosa during the child growing phase.

Mild and hardly noticeable change in the bone metabolism has been reported among the patients with OI treated with oral bisphosphonate even though the definite treatment effect on lumbar spine areal BMD has been shown. Sakkers et al. reported that no significant change was found in urine or serum markers (serum concentrations of creatinine, \( \gamma \)-glutamyl transpeptidase, aspartate and alanine aminotransferases) between the olpadronate and placebo groups. Rauch et al. also showed that there was no significant differences between the risedronate-treated and placebo groups in terms of the serum levels of phosphorus, creatinine, 25-hydroxy vitamin D, 1,25-dihydroxy vitamin D, PTH, urinary calcium/creatinine ratio, alanine aminotransferase, aspartate aminotransferase, and complete blood count. No commonly accepted biochemical markers of bone turnover are used, but it is a public assumption that they can act as a proxy monitoring the efficacy of therapy. The varied markers selected for study in the trials made the direct comparison impossible. These different biological bone turnover markers can help doctors to assess the drug therapeutic effect of the bisphosphonates, drug dosing, and participant compliance.

Bone pain and mobility are the two main key clinical indices that have direct influence on the quality of life of the participants. Improvements in terms of these parameters have been shown in several studies. However, no obvious change in mobility was noted after 2 years of oral bisphosphonates and no improved to bone pain was detected in the trial by Bishop et al. using oral risedronate. One of the possible reasons for this phenomenon is that oral bisphosphonates provided less benefit than IV treatment due to its lower therapeutic effect by oral administration. However, one trial conducted by Chevrel et al. found no difference in self-reported pain scores, with the exception of increased pain with bisphosphonates at 36 months. They also assessed the hearing and found no change in Rinne testing. Taken together, no consistent improvements in these quality-of-life indicators with bisphosphonate administration was demonstrated by the current available literature.

Importantly, oral bisphosphonate administration was associated with few adverse effects. Ward et al. reported that mean bisphosphonate oral bioavailability is similar among the child and adult participants and the individual oral bioavailability varies as much as ten-fold. Chevrel et al. reported that gastrointestinal symptoms were more common in the group of patients treated with alendronate than in those placebo ones, although these symptoms were not responsible for treatment withdrawal. Their results are in contrast with these other four studies, which indicated that gastrointestinal symptoms were not more common in ALN groups than in placebo groups. Based on current evidence, oral bisphosphonate administration treated for 1–3 years appears to be safe and well tolerated in the patients affected with OI. Most of the adverse effects reported in the trials are few and minor including gastrointestinal complaints, fever, headache, nausea, arthralgia, and others, and the drugs are generally well tolerated.

**Conclusion**

Significant improvement in lumbar areal BMD in patients affected with OI have been shown when treated with oral bisphosphonates, even though only a small population was enrolled. We cannot draw a definite conclusion that the increase in BMD can translate into fracture reduction and clinical functional improvement. The optimal method, dose, type, initiation and duration of oral bisphosphonate therapy still remains unclear. Well designed, adequately-powered, placebo-controlled RCTs investigating the effects of oral bisphosphonates on fracture reduction are important to determine improvements to quality of life in both children and adults.
References

1. Ben Amor M, Rauch F, Monti E, Antoniazzi F. Osteogenesis imperfecta. Pediatr Endocrinol Rev, 2013, 10: 397–405.
2. Marin JI, Blissard AR. New genes in bone development: what’s new in osteogenesis imperfecta. J Clin Endocrinol Metab, 2013, 98: 3095–3103.
3. Steiner RD, Pepin MG, Byers PH. Gene Reviews: Osteogenesis Imperfecta Available from: www.genetests.org (accessed 28 January 2005).
4. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet, 1979, 16: 101–116.
5. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet, 2004, 363: 1377–1385.
6. Sykes B, Oglivie D, Words Worth P, et al. Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL 1A1 and COL 1A2. Am J Hum Genet, 1990, 46: 293–307.
7. Byers PH, Wallis GA. W ILING MC. Osteogenesis imperfecta: translation of mutation to phenotype. J Med Genet, 1991, 28: 433–442.
8. Andersen PE Jr, Hauge M. Osteogenesis imperfecta: a genetic, radiological and epidemiological study. Clin Genet, 1989, 36: 250–255.
9. Kuurila K, Grönman R, Johansson R, Kaitila I. Hearing loss in Finnish adults with osteogenesis imperfecta: a nation wide survey. Ann Otol Rhinol Laryngol, 2002, 111: 939–946.
10. Favis MJ. Bisphosphonates for osteoporosis. N Engl J Med, 2010, 363: 2027–2035.
11. Aström E, Söderhäll S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr, 1998, 87: 64–68.
12. Bembii B, Parma A, Bottega M, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr, 1997, 131: 622–625.
13. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med, 1998, 339: 947–952.
14. Aström E, Jorulf H, Söderhäll S. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. Arch Dis Child, 2007, 92: 332–338.
15. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab, 2000, 85: 1846–1850.
16. DiMeglio LA, Ford L, McClintock C, Peacock M. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone, 2004, 35: 1038–1045.
17. Sentilnathan S, Walker E, Bishop NJ. Two doses of pamidronate in infants with osteogenesis imperfecta. Arch Dis Child, 2008, 93: 398–400.
18. Adami S, Gatti D, Colapietro F, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res, 2003, 18: 126–130.
19. Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta; a randomized controlled study. J Bone Miner Res, 2005, 20: 758–763.
20. Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confi rms vertebral gains but not short-term functional improvement. J Bone Miner Res, 2005, 20: 977–986.
21. Kok DH, Sakkers RJ, Janse AJ, et al. Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Iopamidol): a 2-year randomized placebo-controlled trial. Eur J Pediatr, 2007, 166: 1155–1161.
22. Spindler KP, Kuhn JE, Dunn W, Matthews CE, Harrell FE Jr, Dittus RS. Reading and reviewing the orthopaedic literature: asystematic, evidence-based medicine approach. J Am Acad Orthop Surg, 2005, 13: 220–229.
23. Wright RW, Brand RA, Dunn W, Spindler KP. How to write a systematic review. Clin Orthop Relat Res, 2007, 455: 23–29.
24. Von Korff MR, Novak BM, Sacks DB, et al. The depression core: a systematic review of the relationship between depression and pain. Psychosom Med, 1999, 61: 301–315.
25. Jüni T, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ, 2001, 323: 42–46.
26. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org (accessed March 11 2011).
27. Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet, 2004, 363: 1427–1431.
28. Cheveli G, Schott AM, Fontanges E, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomised placebo-controlled trial. J Bone Miner Res, 2006, 21: 300–306.
29. Rauch F, Munns CF, Land C, Cheung M, Glorieux FH. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res, 2009, 24: 1282–1289.
30. Ward LM, Rauch F, Whyte MP, et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab, 2011, 96: 355–364.
31. Bishop N, Adami S, Ahmed SF, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet, 2013, 382: 1424–1427.
32. Bishop N, Harrison R, Ahmed F, et al. A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res, 2010, 25: 32–40.
33. Bradbury LA, Barlow S, Geoghegan F, et al. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int, 2012, 23: 285–294.
34. Rauch F, Travers R, Munns C, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res, 2004, 19: 1191–1193.
35. Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long term therapy. J Clin Endocrinol Metab, 2006, 91: 511–516.
36. Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res, 2003, 18: 610–614.
37. Land C, Rauch F, Munns CF, Sahebnejad S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone, 2006, 39: 901–906.
38. Munns CF, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res, 2005, 20: 1235–1243.
39. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res, 2006, 21: 132–140.
40. Aström E, Söderhäll S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child, 2002, 86: 356–364.
41. Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta -lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab, 2002, 15: 163–174.
42. Ward LM, Denker AE, Porras A, et al. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab, 2005, 90: 4041–4056.
43. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A, 1999, 96: 133–138.